drugset / Trial / NCT01265446

Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

NCT01265446

Phase 3 Completed 250 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

Timeline

Start
2010-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 1 mg Oral
Subject Lidocaine Other / unclassified 8 mg Oral
Background Cetylpyridinium Small molecule 2 mg Oral

Indications

No indication recorded.